Abstract
This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations. During cycle 1, patients received oral ibrutinib 560 mg qd alone (Days 1-4 and 14-18), and ibrutinib 140 mg (Days 5-13; 19-27) plus erythromycin 500 mg tid (Days 5-11) and voriconazole 200 mg bid (Days 19-25). Twenty-six patients (median [range] age: 64.5 [50-88] years) were enrolled. Geometric mean ratio (90% confidence intervals) after co-administration of ibrutinib 140 mg with erythromycin and voriconazole was 74.7 (53.97-103.51) and 143.3 (107.77-190.42), respectively, versus ibrutinib 560 mg alone. The most common (≥20%) adverse events were diarrhea (27%) and neutropenia (23%). The results demonstrate that ibrutinib 140 mg with voriconazole or erythromycin provides exposure within the clinical range for patients with B-cell malignancies.
References
May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Mar 1, 1993·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Apr 4, 2006·Clinical Pharmacology and Therapeutics·Teijo I SaariKlaus T Olkkola
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 25, 2008·Blood·Michael HallekUNKNOWN International Workshop on Chronic Lymphocytic Leukemia
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Dec 18, 2013·The Lancet Oncology·Susan O'BrienJohn C Byrd
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Aug 26, 2014·The Lancet Oncology·Paolo Ghia
Dec 10, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ellen ScheersGeert Mannens
Mar 1, 2015·Cancer Chemotherapy and Pharmacology·Jan de JongErik Mannaert
Jul 15, 2015·Pharmacology Research & Perspectives·Jan de JongErik Mannaert
Sep 19, 2015·British Journal of Clinical Pharmacology·Ronald de VriesJan de Jong
Oct 29, 2015·Bioanalysis·Ronald de VriesTom Verhaeghe
Jul 2, 2016·Clinical Pharmacology and Therapeutics·L de ZwartM Monshouwer
Citations
Jan 12, 2019·Leukemia & Lymphoma·Benjamin W TehMonica A Slavin
Aug 7, 2019·Clinical Pharmacokinetics·Nikki BlosserDouglas Stewart
Aug 1, 2019·Rapid Communications in Mass Spectrometry : RCM·Jiangnan DongGuangxuan Liu
Oct 31, 2019·Clinical and Translational Science·Tuija TapaninenJanne T Backman
Oct 14, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Georgios ChamilosDimitrios P Kontoyiannis
Jun 7, 2020·Journal of Hematology & Oncology·Camille Hardy-AbeloosJanice Gabrilove
Sep 19, 2020·Pharmacology Research & Perspectives·Jan de JongPeter Hellemans
May 13, 2020·Journal of Hematology & Oncology·Wei XuJianyong Li
Oct 7, 2020·Blood Advances·Constantine S TamIan W Flinn
May 30, 2019·American Journal of Therapeutics·Takeo YasuToyotaka Kawamata
May 29, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuqin SongJun Zhu
Nov 9, 2019·Blood Reviews·Rossana MaffeiRoberto Marasca
Dec 4, 2020·Pharmaceuticals·Alejandro Cabrera-AndradeEduardo Tejera
Aug 11, 2021·Expert Review of Hematology·Hee Jeong ChoSang Kyun Sohn
Dec 20, 2021·Therapeutic Drug Monitoring·Benjamin KablyEliane M Billaud